Kfh - Oakland
- Type
- Teaching hospital
- Where
- OAKLAND, CA
- Medicare CCN
- 050075
- Received
- $4,386,494 in 193 records, 2021 ($61,647 general, $4,324,847 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 22 | $61,647 |
| 2021 | Research payment | 171 | $4,324,847 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Amarin Pharma, Inc. | 5 | $1,312,396 | 2021 |
| Merck Sharp & Dohme LLC | 33 | $1,202,324 | 2021 |
| Edwards Lifesciences Corporation | 15 | $623,515 | 2021 |
| JAZZ PHARMACEUTICALS INC. | 4 | $354,801 | 2021 |
| SEAGEN INC. | 22 | $214,777 | 2021 |
| F. Hoffmann-La Roche AG | 27 | $183,580 | 2021 |
| Genentech, Inc. | 26 | $143,324 | 2021 |
| E.R. Squibb & Sons, L.L.C. | 6 | $108,598 | 2021 |
| Johnson & Johnson Health Care Systems Inc. | 18 | $59,614 | 2021 |
| PUMA BIOTECHNOLOGY, INC. | 5 | $58,960 | 2021 |
| Intercept Pharmaceuticals, Inc. | 13 | $35,669 | 2021 |
| Astellas Pharma Global Development | 1 | $26,000 | 2021 |
| Nevro Corp. | 4 | $24,014 | 2021 |
| Surgalign Spine Technologies, Inc. | 3 | $18,945 | 2021 |
| W. L. Gore & Associates, Inc. | 1 | $10,000 | 2021 |
| Novocure Inc. | 6 | $7,940 | 2021 |
| LeMaitre Vascular, Inc. | 1 | $1,800 | 2021 |
| BIOTRONIK INC. | 2 | $119 | 2021 |
| Stryker Corporation | 1 | $113 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 171 | $4,324,847 |
| Debt forgiveness | 21 | $59,847 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $1,800 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $103,967 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Admini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $53,569 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $40,170 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,813 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $868 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Admini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $631 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $541 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $450 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $450 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $270 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $131 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Stryker Corporation | $113 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-30 | LeMaitre Vascular, Inc. | $1,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | RESTOREFLO Device, RESTOREFLO | 2021 | |
| 2021-12-29 | Edwards Lifesciences Corporation | $285,287 | Research payment | Cash or cash equivalent | Clinical Characteristics and Outcomes of Patients with Asymptomatic, Moderate Severity Aortic Stenosis | 2021 | |
| 2021-12-29 | JAZZ PHARMACEUTICALS INC. | $90,000 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | 2021 |
| 2021-12-29 | JAZZ PHARMACEUTICALS INC. | $42,500 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | 2021 |
| 2021-12-24 | Genentech, Inc. | $21,014 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-12-22 | Intercept Pharmaceuticals, Inc. | $2,735 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-12-21 | Amarin Pharma, Inc. | $500,000 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | MITIGATE COVID-19 Study | 2021 |
| 2021-12-21 | PUMA BIOTECHNOLOGY, INC. | $11,116 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2021 |
| 2021-12-20 | Johnson & Johnson Health Care Systems Inc. | $12 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-16 | Edwards Lifesciences Corporation | $14,875 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2021 | |
| 2021-12-09 | Astellas Pharma Global Development | $26,000 | Research payment | Cash or cash equivalent | XOSPATA Drug, ONCOLOGY | Randomized Trial of Gilteritinib vs Midostaurin in FL T3 Mutated Acute Myeloid Leukemia | 2021 |
| 2021-12-08 | Genentech, Inc. | $21,550 | Research payment | Cash or cash equivalent | Drug | ATEZO OR PEMBRO PLUS CHEMO WITH OR WITHOUT TIRAGOLUMAB IN 1L NSCLC SKYSCRAPER 06 | 2021 |
| 2021-12-08 | Genentech, Inc. | $3,050 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2021 |
| 2021-12-08 | SEAGEN INC. | $1,966 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-12-08 | Intercept Pharmaceuticals, Inc. | $270 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-12-06 | Genentech, Inc. | $650 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $208 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-12-01 | Johnson & Johnson Health Care Systems Inc. | $5 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-11-18 | W. L. Gore & Associates, Inc. | $10,000 | Research payment | Cash or cash equivalent | GORE-TEX Vascular Graft Device, Devices | Gore Research and Development | 2021 |
| 2021-11-18 | Novocure Inc. | $2,155 | Research payment | Cash or cash equivalent | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2021 | |
| 2021-11-18 | Novocure Inc. | $85 | Research payment | Cash or cash equivalent | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2021 | |
| 2021-11-17 | Intercept Pharmaceuticals, Inc. | $1,227 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-11-15 | Genentech, Inc. | $21,550 | Research payment | Cash or cash equivalent | Drug | A PHASE III TRIAL OF GDC 9545 IN COMBINATION WITH PALBO IN HR HER2 NEG 1L MBC | 2021 |
| 2021-11-12 | Edwards Lifesciences Corporation | $2,852 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2021 | |
| 2021-11-10 | Johnson & Johnson Health Care Systems Inc. | $150 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-11-08 | Nevro Corp. | $150 | Research payment | Cash or cash equivalent | Omnia Device, Spinal Cord Stimulator | Post Market Study | 2021 |
| 2021-11-08 | Johnson & Johnson Health Care Systems Inc. | $21 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-11-07 | Genentech, Inc. | $2,704 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IPATASERTIB IN COMBINATION WITH PACLITAXEL IN TNBC AND HR BREAST CANCER | 2021 |
| 2021-11-04 | Edwards Lifesciences Corporation | $137,575 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2021 | |
| 2021-11-04 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-04 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-04 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-04 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-03 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-11-03 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-10-29 | Surgalign Spine Technologies, Inc. | $10,080 | Research payment | Cash or cash equivalent | FORTILINK-C IBF SYSTEM Device, MUSCULOSKELETAL | EVoluSIon | 2021 |
| 2021-10-28 | Edwards Lifesciences Corporation | $8,750 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-10-27 | Intercept Pharmaceuticals, Inc. | $577 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-10-20 | Intercept Pharmaceuticals, Inc. | $1,227 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-10-20 | Genentech, Inc. | $592 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-10-20 | Genentech, Inc. | $592 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-10-18 | Edwards Lifesciences Corporation | $6,771 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-10-13 | SEAGEN INC. | $10,409 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-10-13 | SEAGEN INC. | $5,300 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-10-11 | Johnson & Johnson Health Care Systems Inc. | $20 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-10-07 | Novocure Inc. | $1,765 | Research payment | Cash or cash equivalent | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2021 | |
| 2021-10-06 | SEAGEN INC. | $6,461 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-09-30 | Amarin Pharma, Inc. | $176,919 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | MITIGATE COVID-19 Study | 2021 |
| 2021-09-23 | Edwards Lifesciences Corporation | $15,376 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-09-22 | Intercept Pharmaceuticals, Inc. | $1,227 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-09-21 | Genentech, Inc. | $4,950 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2021 |
| 2021-09-15 | SEAGEN INC. | $25,660 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-09-13 | Johnson & Johnson Health Care Systems Inc. | $116 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-09-10 | Genentech, Inc. | $3,700 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | TECENTRIQ ONCOLOGY EXTENSION STUDY | 2021 |
| 2021-09-08 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-09-03 | Amarin Pharma, Inc. | $67,738 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | Residual Risk | 2021 |
| 2021-09-02 | Surgalign Spine Technologies, Inc. | $6,759 | Research payment | Cash or cash equivalent | FORTILINK-C IBF SYSTEM Device, MUSCULOSKELETAL | EVoluSIon | 2021 |
| 2021-08-27 | PUMA BIOTECHNOLOGY, INC. | $17,579 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2021 |
| 2021-08-27 | Genentech, Inc. | $2,564 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $1,778 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $1,185 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $1,185 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $786 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $592 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $592 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-27 | Genentech, Inc. | $592 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2021 |
| 2021-08-23 | Genentech, Inc. | $7,995 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2021 |
| 2021-08-18 | SEAGEN INC. | $13,545 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-08-18 | Intercept Pharmaceuticals, Inc. | $1,227 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-08-13 | PUMA BIOTECHNOLOGY, INC. | $3,303 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2021 |
| 2021-08-12 | Edwards Lifesciences Corporation | $9,414 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-08-04 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2021 |
| 2021-08-02 | Edwards Lifesciences Corporation | $24,720 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-07-30 | Novocure Inc. | $2,155 | Research payment | Cash or cash equivalent | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2021 | |
| 2021-07-30 | BIOTRONIK INC. | $105 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-07-29 | Johnson & Johnson Health Care Systems Inc. | $7,344 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-07-29 | Johnson & Johnson Health Care Systems Inc. | $2,497 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-07-29 | Nevro Corp. | $959 | Research payment | Cash or cash equivalent | Omnia Device, Spinal Cord Stimulator | Post Market Study | 2021 |
| 2021-07-28 | Merck Sharp & Dohme LLC | $241,768 | Research payment | Cash or cash equivalent | GARDASIL Biological, VACCINE | Cohort 0 Kaiser Study | 2021 |
| 2021-07-27 | E.R. Squibb & Sons, L.L.C. | $57,324 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2021 |
| 2021-07-21 | Intercept Pharmaceuticals, Inc. | $3,783 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-07-21 | SEAGEN INC. | $2,973 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-07-21 | SEAGEN INC. | $2,400 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2021 |
| 2021-07-14 | Intercept Pharmaceuticals, Inc. | $11,405 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-07-13 | Genentech, Inc. | $10,000 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-07-13 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-07-13 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-07-13 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-07-13 | Genentech, Inc. | $1,046 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-07-09 | Surgalign Spine Technologies, Inc. | $2,106 | Research payment | Cash or cash equivalent | FORTILINK-TS IBF SYSTEM Device, MUSCULOSKELETAL | EVoluSIon | 2021 |
| 2021-07-08 | Edwards Lifesciences Corporation | $35,139 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-06-24 | F. Hoffmann-La Roche AG | $34,650 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2021 |
| 2021-06-24 | F. Hoffmann-La Roche AG | $1,860 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2021 |
| 2021-06-24 | F. Hoffmann-La Roche AG | $470 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2021 |
| 2021-06-23 | Intercept Pharmaceuticals, Inc. | $7,051 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-06-22 | F. Hoffmann-La Roche AG | $173 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-06-18 | Johnson & Johnson Health Care Systems Inc. | $17,539 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-18 | Johnson & Johnson Health Care Systems Inc. | $17,539 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-18 | Johnson & Johnson Health Care Systems Inc. | $3,689 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-18 | Johnson & Johnson Health Care Systems Inc. | $2,587 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-09 | SEAGEN INC. | $3,200 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-06-03 | SEAGEN INC. | $10,950 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-05-27 | PUMA BIOTECHNOLOGY, INC. | $13,315 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2021 |
| 2021-05-26 | JAZZ PHARMACEUTICALS INC. | $133,381 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2021 |
| 2021-05-25 | Johnson & Johnson Health Care Systems Inc. | $3,196 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-20 | E.R. Squibb & Sons, L.L.C. | $1,500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA Nivo in HL Pediatric (nivo+bv) | 2021 |
| 2021-05-20 | Novocure Inc. | $1,270 | Research payment | Cash or cash equivalent | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2021 | |
| 2021-05-19 | SEAGEN INC. | $1,875 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-05-10 | Amarin Pharma, Inc. | $500,000 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | MITIGATE COVID-19 Study | 2021 |
| 2021-05-06 | Edwards Lifesciences Corporation | $33,763 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2021 | |
| 2021-05-06 | E.R. Squibb & Sons, L.L.C. | $9,965 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks i | 2021 |
| 2021-05-06 | Edwards Lifesciences Corporation | $1,773 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2021 | |
| 2021-04-29 | Nevro Corp. | $2,877 | Research payment | Cash or cash equivalent | Omnia Device, Spinal Cord Stimulator | Post Market Study | 2021 |
| 2021-04-28 | Genentech, Inc. | $2,700 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | MY PATHWAY | 2021 |
| 2021-04-28 | E.R. Squibb & Sons, L.L.C. | $893 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myel | 2021 |
| 2021-04-27 | SEAGEN INC. | $10,192 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-04-21 | Intercept Pharmaceuticals, Inc. | $1,874 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-04-16 | F. Hoffmann-La Roche AG | $26,345 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-04-16 | F. Hoffmann-La Roche AG | $2,865 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-04-16 | F. Hoffmann-La Roche AG | $2,330 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-04-14 | JAZZ PHARMACEUTICALS INC. | $88,920 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2021 |
| 2021-04-09 | Genentech, Inc. | $25,450 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2021 |
| 2021-04-07 | SEAGEN INC. | $14,023 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-04-06 | F. Hoffmann-La Roche AG | $14,478 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-04-05 | Edwards Lifesciences Corporation | $28,736 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2021 | |
| 2021-04-01 | F. Hoffmann-La Roche AG | $1,000 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-04-01 | F. Hoffmann-La Roche AG | $570 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-31 | F. Hoffmann-La Roche AG | $1,500 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-31 | F. Hoffmann-La Roche AG | $1,000 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-31 | F. Hoffmann-La Roche AG | $570 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-25 | Novocure Inc. | $510 | Research payment | Cash or cash equivalent | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2021 | |
| 2021-03-18 | Edwards Lifesciences Corporation | $18,270 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2021 | |
| 2021-03-17 | Merck Sharp & Dohme LLC | $550,707 | Research payment | Cash or cash equivalent | ZOSTAVAX Biological, VACCINE | Merck Post-Licensure of the Long-Term Effectiveness of Zostavax | 2021 |
| 2021-03-17 | Johnson & Johnson Health Care Systems Inc. | $4,530 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-17 | Intercept Pharmaceuticals, Inc. | $1,311 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-03-17 | Johnson & Johnson Health Care Systems Inc. | $303 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-16 | F. Hoffmann-La Roche AG | $3,635 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2021 |
| 2021-03-13 | F. Hoffmann-La Roche AG | $3,552 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-13 | F. Hoffmann-La Roche AG | $2,600 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-13 | F. Hoffmann-La Roche AG | $447 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-03-12 | Johnson & Johnson Health Care Systems Inc. | $43 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-05 | E.R. Squibb & Sons, L.L.C. | $3,189 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myel | 2021 |
| 2021-02-28 | BIOTRONIK INC. | $13 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-02-26 | F. Hoffmann-La Roche AG | $16,864 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-26 | F. Hoffmann-La Roche AG | $5,128 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-25 | F. Hoffmann-La Roche AG | $21,406 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-25 | PUMA BIOTECHNOLOGY, INC. | $13,645 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2021 |
| 2021-02-25 | F. Hoffmann-La Roche AG | $11,468 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-25 | F. Hoffmann-La Roche AG | $7,893 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-13 | F. Hoffmann-La Roche AG | $9,391 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-13 | F. Hoffmann-La Roche AG | $6,191 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-13 | F. Hoffmann-La Roche AG | $124 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-02-10 | SEAGEN INC. | $55,260 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-02-10 | SEAGEN INC. | $7,915 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-01-29 | Nevro Corp. | $20,028 | Research payment | Cash or cash equivalent | Omnia Device, Spinal Cord Stimulator | Post Market Study | 2021 |
| 2021-01-28 | E.R. Squibb & Sons, L.L.C. | $35,725 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2021 |
| 2021-01-27 | SEAGEN INC. | $8,405 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-01-26 | Intercept Pharmaceuticals, Inc. | $1,749 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-01-21 | Amarin Pharma, Inc. | $67,738 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | Residual Risk | 2021 |
| 2021-01-21 | Johnson & Johnson Health Care Systems Inc. | $15 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-19 | F. Hoffmann-La Roche AG | $6,064 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2021 |
| 2021-01-07 | F. Hoffmann-La Roche AG | $1,000 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2021 |
| 2021-01-04 | Merck Sharp & Dohme LLC | $201,200 | Research payment | Cash or cash equivalent | ZOSTAVAX Biological, VACCINE | Post-licensure Evaluation of the Long Term Effectiveness of Zostavax | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Oakland, CA, county Alameda County, CA, state California; placed by its city name.
| Measure | Place (city or town) Oakland, CA | County Alameda County, CA | State California |
|---|---|---|---|
| Population B01003 | 439,418 | 1,649,473 | 39,287,377 |
| Population, 2020 census P1 | 440,646 | 1,682,353 | 39,538,223 |
| Median age B01002 | 37.9 | 39.0 | 37.9 |
| Under 18 B01001 | 18.9% | 19.8% | 22.0% |
| 65 and over B01001 | 14.7% | 15.4% | 15.7% |
| Households B11001 | 176,584 | 598,246 | 13,548,091 |
| Foreign born B05002 | 27.5% | 34.7% | 27.0% |
| Median household income B19013 | $101,600 | $129,367 | $99,122 |
| Median family income B19113 | $119,871 | $159,585 | $113,346 |
| Per capita income B19301 | $61,757 | $65,862 | $49,513 |
| Poverty rate B17001 | 13.4% | 9.2% | 12.0% |
| Unemployment rate B23025 | 6.4% | 5.4% | 6.6% |
| Civilian labor force B23025 | 250,892 | 908,995 | 20,068,466 |
| Mean commute (minutes) B08013 | 29.8 | 31.0 | 28.7 |
| Bachelor's degree or higher B15003 | 48.7% | 52.2% | 37.1% |
| Housing units B25001 | 191,713 | 637,212 | 14,644,735 |
| Owner-occupied B25003 | 42.3% | 54.4% | 55.9% |
| Renters B25003 | 57.7% | 45.6% | 44.1% |
| Median home value B25077 | $929,900 | $1,090,100 | $734,700 |
| Median gross rent B25064 | $1,979 | $2,357 | $2,036 |
| White, not Hispanic B03002 | 27.8% | 27.4% | 33.8% |
| Black B03002 | 19.7% | 9.3% | 5.2% |
| Hispanic or Latino B03002 | 28.7% | 23.4% | 40.2% |
| Asian B03002 | 15.7% | 32.7% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Oakland, CA.
Comments